We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features.
- Authors
Bellmunt, J; Szczylik, C; Feingold, J; Strahs, A; Berkenblit, A
- Abstract
Temsirolimus, a novel inhibitor of mammalian target of rapamycin, has demonstrated prolonged overall survival and progression-free survival compared with interferon alfa (IFN) in patients with advanced renal cell carcinoma (RCC) and poor prognostic features. Adverse events (AEs) of any causality were previously reported, but AEs that were deemed temsirolimus related are of particular relevance for poor-risk patients and for defining mammalian target of rapamycin inhibitor-specific side-effects.
- Publication
Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Vol 19, Issue 8, p1387
- ISSN
1569-8041
- Publication type
Journal Article
- DOI
10.1093/annonc/mdn066